AstraZeneca Q3 Profit Declines; Raises FY Product Sales Growth Outlook

(RTTNews) - British drug major AstraZeneca (AZN.L, AZN) reported Thursday that its third-quarter profit before tax declined 14 percent to $409 million from last year's $477 million.

Profit after tax for the quarter fell 31 percent to $280 million or $0.23 per share from $406 million or $0.34 per share last year.

Core earnings per share for the quarter were $0.99.

Total revenue for the quarter grew 20 percent to $6.41 billion from $5.34 billion a year earlier. On a constant currency basis, revenues increased 22 percent.

Product sales rose 16 percent to $6.13 billion from last year's $5.27 billion.

For fiscal 2019, AstraZeneca reiterated its outlook for core earnings per share in a range of $3.50 to $3.70. Core operating profit is expected to increase ahead of product sales.

The company now expects full-year product sales on a constant currency basis to increase by a low to mid-teens percentage. The company's prior guidance was for a low double-digit percentage increase.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More